COVID-19 Vaccination and Public Health Countermeasures on Variants of Concern in Canada: Evidence From a Spatial Hierarchical Cluster Analysis.
COVID-19
Canada
machine learning
mobility index
stringency index
vaccination coverage
variants of concern
Journal
JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345
Informations de publication
Date de publication:
31 05 2022
31 05 2022
Historique:
received:
12
07
2021
accepted:
26
04
2022
revised:
23
02
2022
pubmed:
30
4
2022
medline:
3
6
2022
entrez:
29
4
2022
Statut:
epublish
Résumé
There is mounting evidence that the third wave of COVID-19 incidence is declining, yet variants of concern (VOCs) continue to present public health challenges in Canada. The emergence of VOCs has sparked debate on how to effectively control their impacts on the Canadian population. Provincial and territorial governments have implemented a wide range of policy measures to protect residents against community transmission of COVID-19, but research examining the specific impact of policy countermeasures on the VOCs in Canada is needed. Our study objective was to identify provinces with disproportionate prevalence of VOCs relative to COVID-19 mitigation efforts in provinces and territories in Canada. We analyzed publicly available provincial- and territorial-level data on the prevalence of VOCs in relation to mitigating factors, summarized in 3 measures: (1) strength of public health countermeasures (stringency index), (2) the extent to which people moved about outside their homes (mobility index), and (3) the proportion of the provincial or territorial population that was fully vaccinated (vaccine uptake). Using spatial agglomerative hierarchical cluster analysis (unsupervised machine learning), provinces and territories were grouped into clusters by stringency index, mobility index, and full vaccine uptake. The Kruskal-Wallis test was used to compare the prevalence of VOCs (Alpha, or B.1.1.7; Beta, or B.1.351; Gamma, or P.1; and Delta, or B.1.617.2 variants) across the clusters. We identified 3 clusters of vaccine uptake and countermeasures. Cluster 1 consisted of the 3 Canadian territories and was characterized by a higher degree of vaccine deployment and fewer countermeasures. Cluster 2 (located in Central Canada and the Atlantic region) was typified by lower levels of vaccine deployment and moderate countermeasures. The third cluster, which consisted of provinces in the Pacific region, Central Canada, and the Prairies, exhibited moderate vaccine deployment but stronger countermeasures. The overall and variant-specific prevalences were significantly different across the clusters. This "up to the point" analysis found that implementation of COVID-19 public health measures, including the mass vaccination of populations, is key to controlling VOC prevalence rates in Canada. As of June 15, 2021, the third wave of COVID-19 in Canada is declining, and those provinces and territories that had implemented more comprehensive public health measures showed lower VOC prevalence. Public health authorities and governments need to continue to communicate the importance of sociobehavioural preventive measures, even as populations in Canada continue to receive their primary and booster doses of vaccines.
Sections du résumé
BACKGROUND
There is mounting evidence that the third wave of COVID-19 incidence is declining, yet variants of concern (VOCs) continue to present public health challenges in Canada. The emergence of VOCs has sparked debate on how to effectively control their impacts on the Canadian population.
OBJECTIVE
Provincial and territorial governments have implemented a wide range of policy measures to protect residents against community transmission of COVID-19, but research examining the specific impact of policy countermeasures on the VOCs in Canada is needed. Our study objective was to identify provinces with disproportionate prevalence of VOCs relative to COVID-19 mitigation efforts in provinces and territories in Canada.
METHODS
We analyzed publicly available provincial- and territorial-level data on the prevalence of VOCs in relation to mitigating factors, summarized in 3 measures: (1) strength of public health countermeasures (stringency index), (2) the extent to which people moved about outside their homes (mobility index), and (3) the proportion of the provincial or territorial population that was fully vaccinated (vaccine uptake). Using spatial agglomerative hierarchical cluster analysis (unsupervised machine learning), provinces and territories were grouped into clusters by stringency index, mobility index, and full vaccine uptake. The Kruskal-Wallis test was used to compare the prevalence of VOCs (Alpha, or B.1.1.7; Beta, or B.1.351; Gamma, or P.1; and Delta, or B.1.617.2 variants) across the clusters.
RESULTS
We identified 3 clusters of vaccine uptake and countermeasures. Cluster 1 consisted of the 3 Canadian territories and was characterized by a higher degree of vaccine deployment and fewer countermeasures. Cluster 2 (located in Central Canada and the Atlantic region) was typified by lower levels of vaccine deployment and moderate countermeasures. The third cluster, which consisted of provinces in the Pacific region, Central Canada, and the Prairies, exhibited moderate vaccine deployment but stronger countermeasures. The overall and variant-specific prevalences were significantly different across the clusters.
CONCLUSIONS
This "up to the point" analysis found that implementation of COVID-19 public health measures, including the mass vaccination of populations, is key to controlling VOC prevalence rates in Canada. As of June 15, 2021, the third wave of COVID-19 in Canada is declining, and those provinces and territories that had implemented more comprehensive public health measures showed lower VOC prevalence. Public health authorities and governments need to continue to communicate the importance of sociobehavioural preventive measures, even as populations in Canada continue to receive their primary and booster doses of vaccines.
Identifiants
pubmed: 35486447
pii: v8i5e31968
doi: 10.2196/31968
pmc: PMC9159466
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31968Subventions
Organisme : CIHR
ID : FRN 175622
Pays : Canada
Informations de copyright
©Daniel A Adeyinka, Cory Neudorf, Cheryl A Camillo, Wendie N Marks, Nazeem Muhajarine. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 31.05.2022.
Références
PLoS One. 2021 Jun 30;16(6):e0253071
pubmed: 34191818
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
J Public Econ. 2020 Nov;191:104272
pubmed: 33518827
EClinicalMedicine. 2021 May;35:100865
pubmed: 33937735
Vaccine. 2022 Apr 14;40(17):2506-2513
pubmed: 33958223
PLoS One. 2021 Jun 4;16(6):e0252405
pubmed: 34086744
JAMA. 2021 Mar 2;325(9):821-822
pubmed: 33507218
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99
pubmed: 33476315
Lancet Public Health. 2020 May;5(5):e261-e270
pubmed: 32220655
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
Vaccine. 2021 Oct 8;39(42):6296-6301
pubmed: 34538699
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
CMAJ. 2021 Apr 26;193(17):E592-E600
pubmed: 33827852
Nat Commun. 2021 May 25;12(1):3118
pubmed: 34035295
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Public Health Rep. 2021 Mar-Apr;136(2):245-252
pubmed: 33400622
J Econ Behav Organ. 2021 Apr;184:199-231
pubmed: 33551525
N Engl J Med. 2021 May 20;384(20):1885-1898
pubmed: 33725432
Lancet. 2021 Mar 13;397(10278):952-954
pubmed: 33581803